Bioporto AS
2P4
Company Profile
Business description
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.
Contact
Tuborg Havnevej 15
Ground Floor
HellerupDK-2900
DNKT: +45 45290000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,126.90 | 73.70 | 0.92% |
| CAC 40 | 7,790.71 | 125.37 | -1.58% |
| DAX 40 | 22,163.49 | 298.03 | -1.33% |
| Dow JONES (US) | 42,001.76 | 417.86 | 1.00% |
| FTSE 100 | 8,582.81 | 76.04 | -0.88% |
| HKSE | 23,184.23 | 64.65 | 0.28% |
| NASDAQ | 17,299.29 | 23.70 | -0.14% |
| Nikkei 225 | 35,585.51 | 32.05 | -0.09% |
| NZX 50 Index | 12,312.60 | 42.60 | 0.35% |
| S&P 500 | 5,611.85 | 30.91 | 0.55% |
| S&P/ASX 200 | 7,925.20 | 81.80 | 1.04% |
| SSE Composite Index | 3,345.86 | 10.11 | 0.30% |